Clinical bottom line
Tumor-associated macrophages (TAMs) represent a heterogeneous population within the tumor microenvironment that can adopt pro-tumoral (M2-like) or anti-tumoral (M1-like) phenotypes. Emerging evidence implicates M2-polarized TAMs in mediating immunosuppression and resistance to immune checkpoint inhibitors (ICIs) across multiple solid tumors. Targeting TAM polarization pathways, including novel molecular regulators and immune inhibitory receptors, may enhance immunotherapy efficacy. However, clinical translation remains in early stages, and robust predictive biomarkers and validated therapeutic strategies are lacking. Clinicians should be aware of TAM polarization as a putative mechanism of immunotherapy resistance warranting further validation and clinical trial assessment.
What the evidence shows
TAM polarization is a dynamic process influenced by tumor-derived signals and metabolic pathways, shaping the immune landscape and therapeutic response. M2-like TAMs promote tumor progression by secreting immunosuppressive cytokines, remodeling extracellular matrix, and inhibiting cytotoxic T cell activity. Conversely, M1-like TAMs support anti-tumor immunity (Saeed Abdullah et al., 2025).
Recent preclinical and translational studies highlight specific targets to modulate TAM polarization and overcome immunotherapy resistance. Cai et al. (2024) demonstrated that inhibition of SRSF10 suppresses M2 polarization in hepatocellular carcinoma, potentiating anti-PD-1 therapy efficacy. Similarly, Chen et al. (2021) reported that blocking the immune inhibitory receptor ILT4 reverses TAM-mediated immunosuppression and restores dysfunctional T cell responses in EGFR-mutant non-small cell lung cancer (NSCLC), enhancing anti-PD-L1 therapy outcomes.
Metabolic regulation of TAM polarization is an emerging area. Hu et al. (2026) reviewed the tumor metabolism-ferroptosis axis as a modulator of TAM phenotype, suggesting that targeting ferroptosis pathways may reprogram TAMs toward an anti-tumoral state. Zhang et al. (2023) further characterized TAM subsets and their plasticity, underscoring the complexity of targeting these cells therapeutically.
Therapeutic strategies under investigation include small molecules, antibodies, and engineered peptides designed to shift TAMs from an M2- to M1-like phenotype or to restore phagocytic function (Moffat et al., 2025; unpublished data from bioregulator peptide studies). These approaches aim to synergize with ICIs by alleviating TAM-driven immunosuppression.
Caveats and uncertainty
Most data on TAM polarization and targeting derive from preclinical models or early-phase translational studies with limited patient cohorts. The heterogeneity of TAM subsets and plasticity complicate the identification of universal biomarkers or therapeutic targets. Furthermore, the tumor type, stage, and microenvironmental context influence TAM behavior and response to modulation.
Clinical trials specifically evaluating TAM-targeted therapies in combination with ICIs are ongoing but have yet to establish definitive efficacy or safety profiles. The potential for off-tumor effects and impact on normal tissue macrophages remains a concern. Additionally, the interplay between TAMs and other immune or stromal cells is incompletely understood, limiting mechanistic insights.
Validated assays to quantify TAM polarization states in patient samples and to monitor treatment-induced changes are not yet standardized, posing challenges for clinical implementation.
How this may change practice
Recognition of TAM polarization as a contributor to immunotherapy resistance may inform patient stratification and therapeutic decision-making in the future. Incorporating TAM-targeted agents into immunotherapy regimens could enhance response rates, particularly in tumors with high M2-like TAM infiltration or known resistance to ICIs.
Clinicians should consider emerging clinical trial data on TAM modulation and remain alert to biomarker developments that may guide personalized immunotherapy strategies. Multidisciplinary collaboration including pathology and translational research teams will be essential to integrate TAM assessment into clinical workflows.
Ultimately, TAM polarization represents a promising but still investigational axis for overcoming immunotherapy resistance in solid tumors. Ongoing research may yield novel combination therapies that improve outcomes for patients with refractory disease.